Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance

Liver International

Volumn 37, Issue 5, 2017, Pages 757-764

  Russo, Mark W ^a   Steuerwald, Nury ^a   Norton, Harry J ^a   Anderson, William E ^a   Foureau, David ^a   Chalasani, Naga ^b   Fontana, Robert J ^c   Watkins, Paul B ^d   Serrano, Jose ^e   Bonkovsky, Herbert L ^f  

^a LEVINE CANCER INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

albumin; drugs; hepatotoxicity; herbals; prognosis

Indexed keywords

ALBUMIN; AMIODARONE; AMLODIPINE; ANTILEUKEMIC AGENT; ASPARAGINASE; CARBAMAZEPINE; CIPROFLOXACIN; MICRORNA; MICRORNA 122; MICRORNA 1246; MICRORNA 1281; MICRORNA 4270; MICRORNA 4274; MICRORNA 4433; MICRORNA 4463; MICRORNA 4484; MICRORNA 4532; MICRORNA 455 3P; MICRORNA 4767; NAFCILLIN; NICOTINIC ACID; NITROFURANTOIN; OXACILLIN; PHENYTOIN; PROTEIN TYROSINE KINASE INHIBITOR; SERUM ALBUMIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VINCRISTINE; XL 999; BIOLOGICAL MARKER; MIRN122 MICRORNA, HUMAN;

ACUTE LIVER FAILURE; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD LEVEL; CLINICAL OUTCOME; CLINICAL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; SURVIVOR; TOXIC HEPATITIS; AGED; BLOOD; CASE CONTROL STUDY; LIVER TRANSPLANTATION; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; UNITED STATES;

ADULT; AGED; BIOMARKERS; CASE-CONTROL STUDIES; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 85028873398     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13312     Document Type: Article

References (34)

1. Regev A, Björnsson ES. Drug-induced liver injury: morbidity, mortality and Hy's Law. Gastroenterology. 2014;147:204.
2. Reuben A, Koch DG, Lee WM, Acute Liver Failure Study Group. Drug induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52:2065–2076.
3. Bonkovsky HL, Jones DP, Russo MW, Shedlofksy SI. Chapter 25–Drug Induced Liver Injury. In: Boyer TD, Manns MP, Sanyal AJ, eds. Zakim and Boyer's Hepatology A Textbook of Liver Disease, 6th edn. Philadelphia: Elsevier Saunders; 2012:417–461.
4. Zimmerman HY. Hepatotoxicity The Adverse Effects of Drugs and Other Chemicals in the Liver, 2nd edn. Baltimore: Lippincott Williams & Wilkins; 1999.
5. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32:55–65.
6. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut. 1999;44:731–735.
7. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10 year period. Gastroenterology. 2005;129:512–521.
8. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug induced hepatic injuries: a French population based study. Hepatology. 2002;36:451–455.
9. Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–1425.
10. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug induced liver injury: the DILIN prospective study. Gastroenterology. 2015;248:1340–1352.
11. Jiang X, Tsitsiou E, Herrick SE, Lindsay MA. MicroRNAs and the regulation of fibrosis. FEBS J. 2010;277:2015–2021.
12. Saito Y, Suzuki H, Matsuura M, et al. MicroRNAs in hepatobiliary and pancreatic cancers. Front Genet. 2011;2:1–6.
13. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One. 2011;6:e23937.
14. Haider BA, Baras AS, McCall MN, Hertel HA, Cornish TC, Halusha MK. A critical evaluation of microRNA biomarkers in non-neoplastic disease. PLoS One. 2014;9:e895565.
15. Starckx S, Batheja A, Verheyen GR, et al. Evaluation of miR-122 and other biomarkers in distinct acute liver injury in rats. Toxicol Pathol. 2013;41:795–804.
16. Steuerwald NM, Foureau DM, Norton HJ, et al. Profiles of serum cytokines in acute drug induced liver injury and their prognostic significance. PLoS One. 2013;8:1–15.
17. Antoine DJ, Lewis PS, Goldring CE, Park BK. Are we closer to finding biomarkers for identifying acute drug-induced liver injury? Biomark Med. 2013;7:383–386.
18. Wlodzimirow KA, Estami S, CHamuleau RA, Nieuwoudt M, Abu-Hanna A. Prediction of poor outcome in patients with acute liver failure-systematic review of prediction models. PLoS One. 2012;7:e50953.
19. Tillmann HL, Rockey DC. Improved prediction of the need for liver transplantation in patients with drug induced liver injury? Gastroenterology. 2014;147:1441.
20. Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug induced liver injury. Gastroenterology. 2014;147:109–118.
21. Starkey Lewis PJ, Dear J, Platt V, et al. Circulating microRNAs as potential markers of human drug induced liver injury. Hepatology. 2011;54:1767–1776.
22. Elfimova N, Schlattjan M, Sowa JP, et al. Circulating microRNAs: promising candidates serving as novel biomarkers of acute hepatitis. Front Physiol. 2012;3:1–6.
23. Weiland M, Gao XH, Zhou L, Mi QS. Small RNAs have a large impact. Circulating microRNAS as biomarkers for human diseases. RNA Biol. 2012;9:850–859.
24. Zhang Y, Jia Y, Zheng R, et al. Plasma microRna-122 as a biomarker for viral-, alcohol-, and chemical related hepatic diseases. Clin Chem. 2010;56:1830–1838.
25. Wang Y, Chen T, Tong W. miRNAs and their application in drug induced liver injury. Biomark Med. 2014;8:162–172.
26. Hornby RJ, Starkey Lewis PS, Dear J, Goldring C, Park K. MicroRNAs as potential circulating biomarkers of drug-induced liver injury: key current and future issues for translation to humans. Expert Rev Clin Pharmacol. 2014;7:349–362.
27. Li Y, Masaki T, Lemon SM. miR-122 and the hepatitis C RNA genome: more than just stability. RNA Biol. 2013;10:919–923.
28. Luna JM, Scheel TK, Danino T, et al. Hepatitis C virus RNA functionally sequesters miR-122. Cell. 2015;160:1099–1110.
29. Sedano C, Sarnow P. Interaction of host cell microRNAs with the HCV RNA genome during infection of liver cells. Semin Liver Dis. 2015;35:75–80.
30. Dodurga Y, Yonguc GN, Avci GB, Bagci G, Gonduz C, Satiroglu TN. Investigation of microRNA expression changes in HepG2 cell line in the presence of URG4/URGCP and absence of URG4/URGCP suppressed by RNA interference. Mol Biol Rep. 2012;39:1119–1124.
31. Goff LA, Davilia J, Swerdel MR, et al. Ago2 immunopreciptation identifies microRNAs in human embryonic stem cells and neural precursors. PLoS One. 2009;4:e7192.
32. Ding CF, Chen WQ, Zhu YT, Bo YL, Hu HM, Zheng RH. Circulating microRNAs in patients with polycystic ovary syndrome. Hum Fertil (Camb). 2015;18:22–29.
33. Cui L, Shi Y, Zhou X, Wang X, et al. A set of microRNAs mediate direct conversion human umbilical cord lining-derived mesenchymal stem cells into hepatocytes. Cell Death Dis. 2013;4:e918.
34. Aithal GP, Ramsay L, Daly AK, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology. 2004;39:1430–1440.